Last reviewed · How we verify
Vinblastin
Vinblastin, marketed by The Lymphoma Academic Research Organisation, is a chemotherapy agent primarily indicated for carcinoma of the female breast. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit the drug's competitive positioning and investor confidence.
At a glance
| Generic name | Vinblastin |
|---|---|
| Sponsor | The Lymphoma Academic Research Organisation |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Carcinoma of female breast
- Gestational trophoblastic neoplasia
- Hodgkin's disease
- Kaposi's sarcoma
- Langerhans cell histiocytosis, disseminated
- Malignant tumor of testis
- Metastatic Breast Carcinoma
- Mycosis fungoides
- Non-Hodgkin's lymphoma
Common side effects
- Leukopenia (granulocytopenia)
- Alopecia
- Constipation
- Anorexia
- Nausea
- Vomiting
- Anemia
- Thrombocytopenia
- Abdominal pain
- Numbness of digits (paresthesias)
- Loss of deep tendon reflexes
- Peripheral neuritis
Serious adverse events
- Myocardial infarction
- Cerebrovascular accidents
- Convulsions
- Hemorrhagic enterocolitis
- Eighth cranial nerve damage (deafness, balance difficulties)
- Angina pectoris
- Syndrome of inappropriate secretion of antidiuretic hormone
- Cellulitis (from extravasation)
- Phlebitis (from extravasation)
- Sloughing (from extravasation)
Key clinical trials
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (PHASE3)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (PHASE1, PHASE2)
- Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma (PHASE2)
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (PHASE3)
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (NA)
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinblastin CI brief — competitive landscape report
- Vinblastin updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI